A semaglutide pill exists and is approved for chronic weight management. A tirzepatide pill does not exist in any approved form, and its manufacturer has not announced a programme to create one. Meanwhile a third option arrived in 2026: orforglipron, a small-molecule oral GLP-1 drug that is not an oral version of either. Those three facts explain most of the confusion in this category.
Why peptides resist being swallowed
Semaglutide and tirzepatide are peptides — chains of amino acids. Your digestive system is very good at breaking those down, because that is precisely what it evolved to do with protein. Swallow a peptide drug unprotected and enzymes dismantle it before meaningful amounts reach your bloodstream.
Getting a peptide through that gauntlet requires engineering. Oral semaglutide is co-formulated with SNAC, an absorption enhancer that locally raises pH and helps the molecule cross the stomach lining. Even with it, absolute bioavailability is roughly 0.4–1% in the original formulation and about 1–2% in the reformulated version. Over 98% of each dose does not make it in — which is why oral doses are so much larger than injected ones.
Tirzepatide is a 39-amino-acid peptide and faces the same problem without an equivalent solution developed for it.
The semaglutide pill
Oral semaglutide has been available for type 2 diabetes for several years. In December 2024 a reformulated version with improved absorption was approved, and in December 2025 a once-daily 25 mg oral dose was approved for chronic weight management — the first oral GLP-1 option specifically for weight in that molecule.
The trade-off is administration. Because absorption is so dependent on stomach conditions, oral semaglutide has historically had to be taken on waking, on an empty stomach, with no more than about 4 ounces of plain water, and with a wait of at least 30 minutes before eating, drinking anything else, or taking other oral medications. Miss that window and you have taken a large dose of something that mostly did not absorb.
A weekly injection has no such choreography. That is the actual comparison: daily and procedural versus weekly and simple.
There is no tirzepatide pill
This is where most misinformation sits. No oral tirzepatide is approved, and no compounded oral, sublingual or troche form is an approved product either. Its manufacturer has not announced an oral tirzepatide development programme.
Products marketed as "oral tirzepatide" or "sublingual tirzepatide" are therefore making a claim that no published absorption data supports. The pharmacology problem is real and unsolved for this molecule: putting a 39-amino-acid peptide under the tongue does not overcome it, because the mucosa is not a general-purpose gateway for large peptides. If someone offers you an oral tirzepatide, the correct question is what bioavailability data they have, and the answer is generally none.
Orforglipron is a different drug
In April 2026 orforglipron was approved for obesity — the first small-molecule, non-peptide GLP-1 receptor agonist. Because it is not a peptide, it survives digestion on its own and needs no absorption enhancer, which is why it can be taken once daily at any time of day with or without food or water restrictions (Orforglipron: First Approval, Drugs 2026; trial data in the New England Journal of Medicine).
It is worth being precise: orforglipron is not oral tirzepatide and not oral semaglutide. It is a separate molecule that happens to hit the same receptor, and it is a single GLP-1 agonist rather than the dual GLP-1/GIP mechanism tirzepatide uses.
How to choose
| Oral semaglutide | Injectable semaglutide | Injectable tirzepatide | |
|---|---|---|---|
| Frequency | Daily | Weekly | Weekly |
| Needle | No | Yes, fine subcutaneous | Yes, fine subcutaneous |
| Timing rules | Strict — empty stomach, plain water, wait before eating | None | None |
| Mechanism | GLP-1 | GLP-1 | GLP-1 and GIP |
Needle aversion is the honest reason most people ask about pills, and it deserves a fair hearing rather than a lecture. It is also worth knowing that the injections use very fine subcutaneous needles and that most people who dreaded the first one stop thinking about it by the third.
The practical question is which regimen you will actually follow. A weekly injection you take reliably beats a daily tablet whose timing rules you skip, and the reverse is equally true. That is a conversation to have with a prescriber rather than a decision to make from a table.
What Promise offers
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here — each combined with vitamin B12 — are not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Both are injectable.
We do not offer an oral tirzepatide, and the reason is the one above: no absorption data supports it. Offering it would mean selling something whose central claim we cannot stand behind.
A licensed provider reviews every request and prescribes only when the medication is appropriate for you — or declines. Not everyone qualifies. If you are choosing between options, tirzepatide versus semaglutide compares the two directly, and the metabolic support and fat loss hub covers the category.
The short version
If you want a GLP-1 in tablet form, oral semaglutide and orforglipron are the products that actually exist, and both come with their own trade-offs. If you want tirzepatide specifically, it is an injection — and any pill sold as tirzepatide is a claim without evidence behind it.